Success Story: EB-1A Approved for an Indian Postdoctoral Fellow Without RFE
Client’s Testimonial:
“Receiving the approval would not have been possible without your team dedication, expertise, and the effort you put into presenting my case so thoroughly and strategically. Thank you so much for all the hard work.”
On January 26th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Fellow in the Field of Computational Chemistry (Approval Notice).
General Field: Computational Chemistry
Position at the Time of Case Filing: Postdoctoral Fellow
Country of Origin: India
State of Residence at the Time of Filing: Alabama
Approval Notice Date: January 26th, 2026
Processing Time: 4 months, 21 days
Case Summary:
The treatment of neurodegenerative diseases like Alzheimer's and frontotemporal dementia depends on innovative drug discovery methods that can identify effective therapeutics faster and more cost-efficiently than traditional approaches. This EB-1A case centered on an Indian postdoctoral fellow in the field of computational chemistry who has advanced AI-driven molecular design for drug discovery, with particular focus on developing novel small molecule inhibitors targeting the pathological protein aggregation that drives cognitive decline.
North America Immigration Law Group (NAILG) framed the record around a consistent research narrative that was both technically credible and clinically significant: the client repeatedly demonstrated how AI-powered computational methods can accelerate the identification of therapeutic candidates, validated natural product compounds for treating inflammation and neurodegeneration, and engineered dual-target therapeutics with optimized binding profiles and reduced side effects for Alzheimer's disease treatment.
Evidence of Field Reliance and Peer Trust
NAILG organized the record around independent reliance and peer trust, supported by compelling metrics:
- Publications: 16 peer-reviewed journal articles (6 first-authored or co-first-authored), 19 abstracts (1 first-authored), and 4 book chapters (1 co-first-authored)
- Citations: 456 citations
- Peer review: at least 10 completed reviews for highly regarded scholarly journals
- 4 Recommendation letters
"In conclusion, [The Client]’s research has shaped the trajectory of the computational chemistry field by leveraging AI-driven drug design and cross-disciplinary collaborations to address urgent national healthcare priorities in neurodegenerative disease treatment."
Beyond the numbers, the petition documented that the client's work was being used as a reference point by research teams at leading institutions. This widespread adoption across continents and therapeutic areas demonstrates that the contributions were not isolated but were being integrated into ongoing pharmaceutical development efforts across the global drug discovery community.The Result
The petition was approved in just over 4 months without a Request for Evidence (RFE), demonstrating the strength of the case and the compelling nature of the client's achievements. NAILG is honored to have assisted with this petition and looks forward to the client's continued contributions to precision medicine and therapeutic innovation for neurodegenerative diseases in the United States.